Save time and jump to the most important pieces.
Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "
SC 13G/A - OmniAb, Inc. (0001846253) (Subject)
SC 13G - OmniAb, Inc. (0001846253) (Subject)
SC 13G/A - OmniAb, Inc. (0001846253) (Subject)
EFFECT - OmniAb, Inc. (0001846253) (Filer)
EFFECT - OmniAb, Inc. (0001846253) (Filer)
POS AM - OmniAb, Inc. (0001846253) (Filer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
OmniAb, Inc. (NASDAQ:OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) until its spin-off as an independent publicly traded company as of November 1, 2022. As such, OmniAb will not file a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) for the three months ended September 30, 2022; however, its third quarter financial results have been reported on a Form 8K/A that can be found here. Avista Public Acquisition Corp. II (which changed its name to OmniAb, Inc. in connection with the merger) filed a Form 10-Q under the name of Omn
Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "
First FDA approval of a bispecific antibody discovered using OmniAb technology OmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United States Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI™ (teclistamab) for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 discovered and developed by Janssen scientists using OmniAb's OmniRat® antibody discovery technology. Under the terms
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 continues to be an outstanding year for Ligand, in particular as royalties from our Pelican Expression Technology platform grow into meaningful revenue contributors," said John Higgins, CEO of Ligand. "The business is enjoying good momentum with numerous positive late-stage de
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 is off to a strong start with solid financial performance from our growing roster of royalty-bearing products and great execution from all our core technology platforms," said John Higgins, CEO of Ligand. "We are excited about the potential growth of our business in the years to come as several recently approved pr
Gainers Quanergy Systems, Inc. (NASDAQ:QNGY) jumped 153.9% to close at $3.30 on Friday. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) surged 61.4% to close at $0.92 after jumping 15% on Thursday. Nuvalent, Inc. (NASDAQ:NUVL) shares gained 60.6% to close at $35.34 after the company reported preliminary Phase 1 clinical data from the ARROS-1 trial that support the best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC. Bull Horn Holdings Corp. (NASDAQ:BHSE) jumped 44.7% to close at $11.95. Fangdd Network Group Ltd. (NASDAQ:DUO) gained 36.6% to close at $1.94. Provident Acquisition Corp. (NASDAQ:PAQC) shares jumped 32.7% to close at $11.00. Perfect Corp. and Provident Ac
Gainers Quanergy Systems, Inc. (NASDAQ:QNGY) surged 179% to $3.6301. Nuvalent, Inc. (NASDAQ:NUVL) shares jumped 62% to $35.60 after the company reported preliminary Phase 1 clinical data from the ARROS-1 trial that support the best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) climbed 38% to $0.7860 after jumping 15% on Thursday. Sierra Metals Inc. (NYSE:SMTS) gained 32% to $0.2201. Sierra Metals' largest shareholder and Compañia Minera Kolpa announced Letter of Intent for Sierra Metals transaction and financing. Rail Vision Ltd. (NASDAQ:RVSN) jumped 31.6% to $0.7899. Agrify Corporation (NASDAQ:AGFY) surged 31% to $2.1
First FDA approval of a bispecific antibody discovered using OmniAb technology OmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United States Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI™ (teclistamab) for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 discovered and developed by Janssen scientists using OmniAb's OmniRat® antibody discovery technology. Under the terms o